6-K: Report of foreign private issuer (related to financial reporting)
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
No Data
No Data